Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine plus osimertinib for EGFR exon 21 L858R-mutated advanced NSCLC
ChiCTR2500114640Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of osimertinib and olanzapine in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by China-Japan Friendship Hospital. Primary endpoint: progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
osimertinibolanzapine
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500114640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114640.